Skip to main content
China SXT Pharmaceuticals, Inc. logo

China SXT Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SXTC ISIN · VGG2161P1320 LEI · 5493006HSPECSOT1UH87 US Manufacturing
Open in API
Filings indexed 147 across all filing types
Latest filing 2026-06-01 Capital/Financing Update
Country VG Virgin Islands (British)
Listing US SXTC

About China SXT Pharmaceuticals, Inc.

https://www.sxtchina.com/

China SXT Pharmaceuticals, Inc. is a pharmaceutical company engaged in the research, development, manufacture, marketing, and sales of traditional Chinese medicine products. The company specializes in the production of Advanced Traditional Chinese Medicine Pieces (TCMPs), which are high-quality, precision-processed herbal medicines. Its integrated operations cover the entire product lifecycle, from initial research and development to the final sale and distribution of its products to commercial clients.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 90% confidence The document is a Form 6-K filing by a foreign private issuer reporting the entry into a material definitive agreement establishing an at-the-market equity offering up to $100 million. It describes terms of a sales agreement for issuing and selling Class A ordinary shares, which is a financing activity. This matches the “Capital/Financing Update” category (CAP).
2026-06-01 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 90% confidence The document is a prospectus supplement filed on Form 424(b)(5) relating to an at-the-market equity offering of up to $100 million in Class A Ordinary Shares. It is an SEC prospectus document underpinning a capital raise rather than a full financial report or proxy. This fits the definition of a capital/financing update, as it details a new share issuance and fundraising arrangement through a sales agreement.
2026-06-01 English
424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under a registration statement, describing an offering of 2,000,000 Class A Ordinary Shares by China SXT Pharmaceuticals, Inc. It details the terms of the offering, use of proceeds, risk factors, and legal disclaimers. This type of document is related to capital raising and financing activities, specifically a securities offering. It is not an annual report, earnings release, or any other type of financial or governance report. The presence of terms like 'prospectus supplement', 'offering', 'securities purchase agreement', and detailed share issuance information clearly indicates this is a Capital/Financing Update filing.
2026-04-09 English
6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, China SXT Pharmaceuticals, Inc., with the SEC. It reports the entry into a material definitive agreement related to a securities purchase agreement for issuing shares. The document details the offering, proceeds, and related exhibits but does not contain comprehensive financial statements or detailed financial performance data. The Form 6-K is typically used for current reports by foreign private issuers to disclose material events. The content focuses on a capital raising transaction, which aligns with updates on financing activities or capital structure changes. The document length is 3715 characters, which is relatively short and consistent with a report of a specific event rather than a full financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-04-09 English
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, China SXT Pharmaceuticals, Inc., with the SEC. It details a securities purchase agreement and a registered direct offering of shares and pre-funded warrants, including terms of the offering, proceeds, and placement agency agreement. The content focuses on capital raising activities and financing terms. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a report publication announcement or a certification but a detailed update on financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (6533 characters) supports it being a substantive filing rather than a brief announcement.
2026-01-13 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an offering of Class A Ordinary Shares and Pre-Funded Warrants by China SXT Pharmaceuticals, Inc. It details the terms of the securities offering, pricing, placement agent fees, and regulatory risk factors including references to the Holding Foreign Companies Accountable Act and PCAOB inspection issues. The document is clearly an offering document related to capital raising activities and not a financial report, earnings release, or management discussion. It is not a report publication announcement or a regulatory filing in the sense of certifications or miscellaneous filings. The content matches the definition of a Capital/Financing Update as it provides updates on company fundraising and capital structure changes through a securities offering prospectus supplement.
2026-01-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.